Sanofi's 2-Pen Diabetes Combo Perplexes FDA
Executive Summary
Sanofi SA's strategy of using two pen injectors for its fixed-ratio combination that combines its experimental glucagon-like peptide-1 receptor agonist lixisenatide with its US-approved diabetes drug Lantus (basal insulin glargine) has the FDA perplexed and concerned about the potential for adverse events and medication errors.